IMMUNOMET THERAPEUTICS
ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the quality of life of cancer patients. With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells.
IMMUNOMET THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.immunomet.com
Total Employee:
1+
Status:
Active
Contact:
+119196161923
Email Addresses:
[email protected]
Total Funding:
17.2 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Apache
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
AmXpress
AmXpress is a medicine testing industries that specializes in chromatography products for chemical analysis.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Founder
Investors List
NHN Investment
NHN Investment investment in Venture Round - ImmunoMet Therapeutics
G.N. Tech Venture
G.N. Tech Venture investment in Venture Round - ImmunoMet Therapeutics
SL Investment
SL Investment investment in Venture Round - ImmunoMet Therapeutics
Mirae Asset Venture Investment
Mirae Asset Venture Investment investment in Venture Round - ImmunoMet Therapeutics
SL Investment
SL Investment investment in Series B - ImmunoMet Therapeutics
InterVest
InterVest investment in Series B - ImmunoMet Therapeutics
NHN Investment
NHN Investment investment in Series B - ImmunoMet Therapeutics
Mirae Asset Venture Investment
Mirae Asset Venture Investment investment in Series B - ImmunoMet Therapeutics
G.N. Tech Venture
G.N. Tech Venture investment in Series B - ImmunoMet Therapeutics
Sungwuk Kim
Sungwuk Kim investment in Series B - ImmunoMet Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-07-26 | Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer |
Official Site Inspections
http://www.immunomet.com
- Host name: box2102.bluehost.com
- IP address: 74.220.219.13
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "ImmunoMet Therapeutics"
About - Immunomet
ImmunoMet Therapeutics is a clinical stage biotech targeting cellular metabolism to advance novel anti-cancer and/or anti-fibrosis therapies to patients. Our …See details»
ImmunoMet Therapeutics - Crunchbase Company Profile & Funding
ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the …See details»
Management - Immunomet
Prior to joining ImmunoMet Therapeutics in 2020, Dr. Welsch served as Vice President of Biology at Peloton Therapeutics and earlier as Executive Director of Translation Sciences at BioMed Valley Discoveries, where he led their first-in …See details»
ImmunoMetNet
Local ImmunoMetNet AUMC meetings are up and running! After a couple of successful annual meetings and many online seminars, the time is now for local ImmunoMetNet AUMC series …See details»
ImmunoMet Company Profile 2024: Valuation, Funding
ImmunoMet General Information Description. Developer of novel anti-tumor and immuno-oncology therapies designed to treat cancer patients. The company's therapies include …See details»
ImmunoMet Company Profile - Office Locations, Competitors
ImmunoMet is a clinical-stage biotechnological company that specializes in tumor metabolism and immuno-metabolism. It develops a series of small molecules in its biguanide engine targeting …See details»
ImmunoMet Therapeutics - Contacts, Employees, Board Members, …
Organization. ImmunoMet Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. ... ImmunoMet Therapeutics has …See details»
ImmunoMet Therapeutics, Inc. - Drug pipelines, Patents, Clinical …
Explore ImmunoMet Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 2 news, and 4 literature, Disease Domain ...See details»
ImmunoMet Therapeutics, Inc. Information - RocketReach
ImmunoMet Therapeutics is a clinical stage biotech targeting cellular metabolism to develop novel anti-fibrotic and anti-tumor therapies. Our lead molecule, IM156, is a protein complex 1 (PC1) …See details»
ImmunoMet Therapeutics - Company Profile - Tracxn
Nov 29, 2024 ImmunoMet Therapeutics (a spinoff of HanAll Biopharma) is a development-stage biotechnology company developing oncology products with a focus on cancer metabolism and …See details»
Board of Directors – Immunomet
Dr. Sung-wuk Kim has served as Chairman of the Board of Directors and Chief Executive Officer (CEO) since the founding of ImmunoMet Therapeutics, a spinoff of HanAll Biopharma in July …See details»
ImmunoMet Therapeutics - Overview, News & Similar companies
Jul 26, 2021 ImmunoMet's lead molecu le, IM156, is a PC1 inhibitor and is the first potent PC1 inhibitor to complete Phase 1 with good tolerability. In addition to IM156, ImmunoMet owns a …See details»
ImmunoMet Therapeutics | VentureRadar
ImmunoMet is a clinical stage biotech targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies. Our lead molecule, IM156, is an protein complex 1 (PC1) inhibitor …See details»
Immunomet Intolerance and Dysbiosis - Crunchbase
Apr 19, 2022 Microviable Therapeutics raised €1,500,000 / Seed from Immunomet Intolerance and Dysbiosis. Discover more funding rounds . Details. Edit Details Section. Industries . …See details»
Cash injection sets up first trial of ImmunoMet's lead cancer ...
Mar 8, 2017 The Series B funding top-up will fund a phase 1 trial of oxidative phosphorylation (OXPHOS) inhibitor IM156 due to start in the second quarter, said ImmunoMet's founder and …See details»
Investors and Media - Immunomet
News Release ImmunoMet Therapeutics Announces Acceptance of Abstract for 2020 ASCO Virtual Scientific Program May 20, 2020 - Houston, TexasImmunoMet Therapeutics, a clinical …See details»
European Immunometabolism Network
Follow us: Stay connected and engaged with the European Immunometabolism community through our social media channels. Join us on LinkedIn and Instagram to access the latest …See details»
Scientific Advisors – Immunomet
Professor, Center for Cancer and Cell Biology Program Lead, Metabolic and Nutritional Programming Van Andel Research InstituteSee details»
Pipeline - Immunomet
ImmunoMet Pipeline As a leader in tumor metabolism and fibrosis, ImmunoMet Therapeutics is developing novel chemical entities modulating critical metabolic functions in tumor, fibrotic, …See details»